<DOC>
	<DOCNO>NCT01193491</DOCNO>
	<brief_summary>The purpose study evaluate safety , determine maximum tolerate dose ( MTD ) schedule IPI-493 patient hematologic malignancy .</brief_summary>
	<brief_title>Dose Escalation IPI-493 Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>&gt; /=18 year old ECOG 01 confirm hematological malignancy refractory available therapy therapy available adequate hepatic , renal function active CNS malignancy prolong QT interval significant GI/liver disease serious concurrent illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>MPD</keyword>
	<keyword>Client Proteins</keyword>
	<keyword>Hsp90</keyword>
</DOC>